Septerna, Inc. (SEPN)
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Septerna Inc
No splits on record
Nothing in SEPN's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Revenue | $45.95M | $1.07M | $151K |
| YoY Growth | 4174.5% | 611.9% | - |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $45.95M | $1.07M | $151K |
| Gross Margin | 100.0% | 100.0% | 100.0% |
| Research and Development | $97.58M | $65.34M | $35.98M |
| Selling, General, and Administrative | $29.16M | $16.56M | $9.72M |
| Other | $0 | $0 | -$47.63M |
| Total Operating Expenses | $126.75M | $81.9M | -$1.92M |
| Operating Income (EBIT) | -$80.8M | -$80.82M | $2.08M |
| Operating Margin | -175.8% | -7518.4% | 1374.2% |
| Interest Expense | $0 | $0 | $0 |
| Interest Income | $19.53M | $8.62M | $2.79M |
| Other Income (Expense) | $31.93M | $8.53M | $2.8M |
| Income Before Tax (EBT) | -$48.87M | -$72.3M | $4.87M |
| Income Tax Expense | $12K | -$498K | $691K |
| Net Income | -$48.88M | -$71.8M | $4.18M |
| Net Income Margin | -106.4% | -6678.9% | 2768.2% |
| Supplementary Data | |||
| EPS | -1.10 | -1.93 | 0.03 |
| Diluted EPS | -1.10 | -1.93 | 0.03 |
| Weighted Average OS | 44.26M | 37.19M | 19.50M |
| EBITDA | -$47.26M | -$70.89M | -$44.7M |
| EBITDA Margin | -102.9% | -6594.9% | -29604.0% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $120.72M | $238.2M | $88.48M | $30.61M |
| Short-Term Investments | $270.37M | $112.73M | $0 | $0 |
| Cash and Short-Term Investments | $391.09M | $350.92M | $88.48M | $30.61M |
| Accounts Receivable | $13.74M | $1.12M | $22.78M | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $1.15M | $200K | $92K | $204K |
| Total Current Assets | $410.96M | $356.82M | $112.68M | $31.89M |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $25.93M | $28.69M | $17.19M | $3.1M |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $69.87M | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $159.29M | $1.17M | $1M | $1.12M |
| Total Long-Term Assets | $185.22M | $99.73M | $18.19M | $4.23M |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $596.19M | $456.55M | $130.87M | $36.12M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $10.28M | $3.2M | $2.64M | $3.07M |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $200K | $0 |
| Current Unearned Revenue | $62.27M | $0 | $0 | $0 |
| Other Current Liabilities | $6.07M | $4.21M | $3.04M | $1.76M |
| Total Current Liabilities | $86.93M | $12.85M | $6.91M | $5.54M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $21.41M | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $105.92M | $33K | $149.76M | $74.78M |
| Total Long-Term Liabilities | $127.33M | $23.66M | $162.33M | $74.78M |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $214.26M | $36.51M | $169.24M | $80.32M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $0 | $0 |
| Common Stock | $45K | $44K | $3K | $3K |
| Retained Earnings | -$167.25M | -$118.37M | -$46.58M | -$50.76M |
| Comprehensive Income & Other | $617K | $56K | $0 | $0 |
| Other Stockholders' Equity | $549.13M | $538.38M | $8.2M | $6.55M |
| Total Equity | $381.93M | $420.05M | -$38.37M | -$44.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $596.19M | $456.55M | $130.87M | $36.12M |
| Supplementary Data | ||||
| Total Debt | $23.63M | $25.48M | $12.57M | $710K |
| Net Debt | -$97.1M | -$212.72M | -$75.92M | -$29.9M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$48.88M | -$71.8M | $4.18M | -$27.68M |
| Depreciation & Amortization | $1.6M | $1.4M | $848K | $577K |
| Deferred Income Tax | $0 | -$491K | $491K | $0 |
| Stock-Based Compensation | $8.48M | $3.15M | $1.62M | $1.52M |
| Changes in Working Capital: | ||||
| Accounts Receivable | -$10.19M | -$20K | -$151K | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Accounts Payable | $6.6M | $723K | -$653K | $1.73M |
| Other Working Capital | $166.36M | -$455K | $1.73M | $20K |
| Total Working Capital Change | $162.78M | $248K | $926K | $1.75M |
| Other Non-Cash Items | -$13.79M | $18K | -$46.79M | $530K |
| Net Cash from Operating | $110.19M | -$67.47M | -$38.72M | -$23.3M |
| Investing Activities | ||||
| Capital Expenditures | -$518K | -$2.1M | -$2.88M | -$1.29M |
| Acquisitions | $12.5M | $0 | $0 | $0 |
| Purchases of Investments | -$450.95M | -$213.39M | $0 | $0 |
| Sales of Investments | $209.62M | $32.27M | $0 | $0 |
| Other Investing Activities | $0 | $22.63M | $25M | $0 |
| Net Cash from Investing | -$229.35M | -$160.6M | $22.12M | -$1.29M |
| Financing Activities | ||||
| Debt Repaid | - | - | - | - |
| Common Stock Issuance | $1.69M | $302.79M | $0 | $82K |
| Common Stock Repurchases | -$1K | -$1K | -$1K | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $52K | $0 | $0 |
| Net Cash from Financing | $1.69M | $377.78M | $74.52M | $30.05M |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$117.47M | $149.71M | $57.92M | $5.46M |
| Supplementary Data | ||||
| Operating Cash Flow | $110.19M | -$67.47M | -$38.72M | -$23.3M |
| Capital Expenditure | -$518K | -$2.1M | -$2.88M | -$1.29M |
| Free Cash Flow | $109.67M | -$69.57M | -$41.6M | -$24.59M |
| Cash at Beginning | $239.1M | $89.39M | $31.47M | $26.01M |
| Cash at End | $121.63M | $239.1M | $89.39M | $31.47M |